Levi & Korsinsky调查Syros制药公司停止的第二阶段试验和61%的库存下降。 Levi & Korsinsky investigates Syros Pharmaceuticals for halted Phase 2 trial and 61% stock drop.

Levi & Korsinsky调查Syros制药公司(SYRS)在2024年8月12日宣布停止参加第二阶段临床试验(SELECT-AML-1)后, Levi & Korsinsky investigates Syros Pharmaceuticals (SYRS) after the company's Aug 12, 2024 announcement to halt enrollment in Phase 2 clinical trial, SELECT-AML-1, due to low probability of success. 8月13日股票价格下跌61%。 Stock price fell by 61% on Aug 13. 请遭受损失的投资者与公司联系,了解关于可能采取的法律行动的更多信息。 Investors who suffered losses are invited to contact the firm for more info on potential legal action.